Abbott Laboratories
ABT
NYSE·Healthcare·Medical - Devices·Mkt cap $187.4B
$108.32
▼ -0.43%
P/E
34.83
Mkt Cap
$187.4B
52-Wk Range
$81.97–$137.49
52-Week Range
$81.97 - $137.49
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 18.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Diversified product portfolio across pharmaceuticals, diagnostics, nutrition, and medical devices reducing revenue concentration risk
- Market-leading diagnostic capabilities with rapid testing platforms for infectious diseases and point-of-care systems
- Strong brand recognition and 135+ year operating history with established distribution networks globally
- Recurring revenue streams from diagnostic consumables, generic pharmaceuticals, and nutritional products
- Advanced manufacturing and automation capabilities in laboratory diagnostics and medical devices
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Increasing demand for point-of-care and rapid diagnostic testing in clinical and consumer markets
Value
Fairly valued vs Medical Devices peers
Momentum
Strong
+19.7% over 3m
Quality
Strong
Strong fundamentals
Dividend
Solid
2.29% yield
Smart-money signal
Who's buying ABT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 21, 2026
JUL 16, 2026
Reported EPS of $1.31 vs $1.28 consensus (+2.3% surprise). Revenue of $12.6B vs $12.5B expected (+0.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2.3%
Revenue trend · last 8Q
—
+7%
+4%
+7%
+7%
+4%
+8%
+13%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$10.6B
$11.0B
$10.4B
$11.1B
$11.4B
$11.5B
$11.2B
$12.6B
Margins · last 8Q
Gross
58.0%
Operating
14.2%
Profit
7.4%
Wall Street consensus
15 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Aug 21, 2026
vs Industry
How ABT stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related